BioChain expands line of NGS-characterized biosamples

By The Science Advisory Board staff writers

September 22, 2021 -- The BioChain Institute recently expanded its line of next-generation sequencing-characterized biosamples, the company announced.

The institute said the biosamples encompass a variety of cancer-related mutations available for preclinical drug development and as reference samples for labs that are certified to comply with Clinical Laboratory Improvement Amendments.

BioChain now offers ready-to-use, NGS-characterized tissue samples for BRCA1, BRCA2, microsatellite instability, human papilloma virus, epidermal growth factor receptor, and KRAS, the institute said. It is developing the new mutation-specific biosamples in response to the growing need expressed by researchers for these samples.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter